← Back to patent-cliff list
Etoricoxib
Tier C — Watch / tradeEtoricoxib
Merck & Co Inc
Originator
2002
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：COX-2
Brand：Arcoxia, Nucoxia, Tauxib
Indications (approved)：Osteoarthritis, 痛风性关节炎, Dysmenorrhoea, Rheumatoid arthritis, Ankylosing spondylitis
Regional status
US
-
EU
Approved
2002-04-15
China
Approved
2007-05-21
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Etoricoxib?
Approved indications include: Osteoarthritis, 痛风性关节炎, Dysmenorrhoea, Rheumatoid arthritis, Ankylosing spondylitis.
When does the Etoricoxib patent expire?
No public expiry year is available for Etoricoxib yet; this page updates once verified.
How do I get a quote for Etoricoxib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27